NewAmsterdam Pharma Company N.V.
$35.75+6.02%(+$2.03)
TickerSpark Score
61/100
45
Valuation
40
Profitability
55
Growth
84
Health
80
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAMS research report →
52-Week Range75% of range
Low $16.79
Current $35.75
High $42.20
Companywww.newamsterdampharma.com
NewAmsterdam Pharma Company N. V. , a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
- CEO
- Michael Harvey Davidson Facp.
- IPO
- 2021
- Employees
- 68
- HQ
- Naarden, NL
Price Chart
+84.75% · this period
Valuation
- Market Cap
- $4.18B
- P/E
- -20.35
- P/S
- 185.21
- P/B
- 6.51
- EV/EBITDA
- -16.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.52%
- Op Margin
- -953.59%
- Net Margin
- -942.76%
- ROE
- -29.80%
- ROIC
- -32.35%
Growth & Income
- Revenue
- $22.50M · -50.61%
- Net Income
- $-203,819,000 · 15.64%
- EPS
- $-1.75 · 31.64%
- Op Income
- $-225,683,000
- FCF YoY
- 7.04%
Performance & Tape
- 52W High
- $42.20
- 52W Low
- $16.79
- 50D MA
- $32.38
- 200D MA
- $32.43
- Beta
- 0.03
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on NAMS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 26 | LANGE LOUIS G | sell | 44,173 |
| Mar 11, 26 | LANGE LOUIS G | sell | 446 |
| Mar 9, 26 | LANGE LOUIS G | other | 44,619 |
| Mar 6, 26 | LANGE LOUIS G | sell | 28,186 |
| Mar 9, 26 | LANGE LOUIS G | other | 44,619 |
| Mar 5, 26 | Kastelein Johannes Jacob Pieter | other | 104,467 |
| Mar 6, 26 | Kastelein Johannes Jacob Pieter | other | 94,124 |
| Mar 9, 26 | Kastelein Johannes Jacob Pieter | other | 101,409 |
| Mar 5, 26 | Kastelein Johannes Jacob Pieter | other | 104,467 |
| Mar 9, 26 | Kastelein Johannes Jacob Pieter | other | 101,409 |
Our NAMS Coverage
We haven't published any research on NAMS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NAMS Report →Similar Companies
KYMR+3.21%
Kymera Therapeutics, Inc.
$80.65
VKTX+3.66%
Viking Therapeutics, Inc.
$29.44
IMVT+34.99%
Immunovant, Inc.
$35.49
AKRO+0.00%
Akero Therapeutics, Inc.
$54.65
CRNX+3.81%
Crinetics Pharmaceuticals, Inc.
$36.27
ACLX+0.02%
Arcellx, Inc.
$115.07
PRAX+4.68%
Praxis Precision Medicines, Inc.
$335.61
LGND+4.80%
Ligand Pharmaceuticals Incorporated
$217.75